Medicare reform quietly lets insurers opt out of patient protections

What it does

This bill directs the federal government to audit the most expensive and heavily prior-authorized drugs and medical services in Medicare Advantage plans, then standardize the prior authorization process across all plans by May 2028. However, it exempts providers in risk-sharing arrangements (like accountable care organizations) from these new standardized requirements—and allows insurance plans to opt out of the exemption and keep stricter authorization rules anyway.

Why we flagged it

The bill's core mechanism is a standardization mandate for prior authorization in Medicare Advantage, framed as patient relief. However, the operative exemptions for risk-bearing providers and the plan opt-out clause substantially narrow the reform's scope and may preserve the status quo for many enrollees, making it a partial reform with significant loopholes.

What the text implies

• The exemption for risk-bearing providers (ACOs, section 1115A models) may create a two-tier system where patients in traditional MA plans face stricter prior authorization than those in risk-sharing arrangements, potentially widening access disparities.
• The plan opt-out mechanism allows MA insurers to request continued strict prior authorization even for standardized high-cost services, effectively nullifying the reform for any plan that chooses to maintain barriers—undermining the bill's stated purpose.

The full analysis lists 4 implications of this text.

Who stands to gain

Medicare Advantage insurers (through opt-out flexibility and exemption carve-outs); Accountable care organizations and risk-bearing providers (through prior authorization exemption); Pharmaceutical manufacturers of high-cost drugs (potential for faster authorization in some settings